A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Adenovirus Conjunctivitis

Trial Profile

A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Adenovirus Conjunctivitis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Ganciclovir (Primary)
  • Indications Adenovirus infections; Infectious keratoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Sep 2014 Planned End Date changed from 1 Nov 2013 to 1 Apr 2016, as per ClinicalTrials.gov record.
    • 17 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top